Program
tislelizumab
Also written as “Tislelizumab”, “BGB-A317” and “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Carcinoma, Hepatocellular · Stomach Neoplasms · Hodgkin Disease, led by 21 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 539 open or running | phase 3since Nov 27, 2017 | Mar 26, 2015 | Nov 2026phase 2 · NCT03736889 |
| RemeGen | 22 open or running | phase 3since Apr 17, 2025 | Apr 17, 2025 | May 15, 2028phase 3 · NCT06944496 |
| Antengene | 10 open or running | phase 2since May 25, 2020 | May 25, 2020 | none ahead |
| Beijing Aosaikang Pharmaceutical | 11 open or running | phase 2since Nov 21, 2022 | Nov 21, 2022 | none ahead |
| Beijing Biostar Pharmaceuticals | 11 open or running | phase 2since Sep 18, 2026 | Sep 18, 2026 | Sep 20, 2028phase 2 · NCT07842276 |
| briacell-therapeutics-corporation | 11 open or running | phase 2since Jun 11, 2024 | Jun 11, 2024 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 3since Nov 9, 2018 | Nov 9, 2018 | none ahead |
| Changchun GeneScience Pharmaceutical | 10 open or running | phase 1since Jun 16, 2022 | Jun 16, 2022 | none ahead |
| HUTCHMED | 10 open or running | phase 2since Sep 23, 2020 | Sep 23, 2020 | none ahead |
| immix-biopharma-inc | 11 open or running | phase 2since Jan 4, 2023 | Jan 4, 2023 | none ahead |
| immune-onc-therapeutics | 10 open or running | phase 1since Aug 12, 2022 | Aug 12, 2022 | none ahead |
| Jazz Pharmaceuticals | 11 open or running | phase 3since Nov 5, 2021 | Nov 5, 2021 | none ahead |
| jiangsu-healthy-life-innovation-medical-technology-co-ltd | 11 open or running | phase 2since Mar 19, 2024 | Mar 19, 2024 | none ahead |
| jiangsu-yahong-meditech-co-ltd-aka-asieris | 10 open or running | phase 2since Mar 21, 2021 | Mar 21, 2021 | none ahead |
| Leap Therapeutics | 10 open or running | phase 2since Apr 23, 2020 | Apr 23, 2020 | none ahead |
| Nanjing Leads Biolabs | 10 open or running | phase 2since Aug 22, 2022 | Aug 22, 2022 | none ahead |
| Novartis | 10 open or running | phase 3since Mar 17, 2023 | Mar 17, 2023 | none ahead |
| shanghai-gopherwood-biotech-co-ltd | 10 open or running | phase 2since Aug 15, 2022 | Aug 15, 2022 | none ahead |
| shanghai-kanda-biotechnology-co-ltd | 11 open or running | phase 2since May 24, 2023 | May 24, 2023 | none ahead |
| Sino Biopharmaceutical | 11 open or running | phase 2since Feb 9, 2025 | Feb 9, 2025 | none ahead |
| Suzhou Zelgen Biopharmaceuticals | 11 open or running | phase 2since Jul 25, 2025 | Jul 25, 2025 | Dec 2027phase 2 · NCT07099547 |
Also a collaborator on its studies: Myriad Genetic Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Oct 17, 2018.
- Mar 17, 2023Novartis’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to NovartisNovartis · NCT05791097
- May 24, 2023shanghai-kanda-biotechnology-co-ltd’s first study: phase 2 study in Advanced HCCNew to shanghai-kanda-biotechnology-co-ltdshanghai-kanda-biotechnology-co-ltd · NCT05906524 · 85 planned · China
- Jul 31, 2023Phase 1 study in Advanced Solid TumorBeOne Medicines · NCT05981703 · 337 planned · United States, Australia, China and more
- Oct 16, 2023Phase 1 study in Carcinoma, Non-Small-Cell LungBeOne Medicines · NCT06091943 · 62 enrolled · China, Georgia, Moldova
- Mar 19, 2024jiangsu-healthy-life-innovation-medical-technology-co-ltd’s first study: phase 2 study in GlioblastomaNew to jiangsu-healthy-life-innovation-medical-technology-co-ltdjiangsu-healthy-life-innovation-medical-technology-co-ltd · NCT06353360 · 30 planned · China
- Jun 11, 2024briacell-therapeutics-corporation’s first study: phase 2 study in Breast NeoplasmsNew to briacell-therapeutics-corporationbriacell-therapeutics-corporation · NCT06471673 · 18 planned · United States
- Feb 9, 2025Sino Biopharmaceutical’s first study: phase 2 study in Advanced Solid TumorNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06825494 · 194 planned · China
- Apr 17, 2025RemeGen’s first study: phase 3 study in Stomach NeoplasmsNew to RemeGenRemeGen · NCT06944496 · 616 planned · China
- Jun 20, 2025Phase 3 study in Metastatic Gastric AdenocarcinomaBeOne Medicines · NCT07043400 · 351 planned · United States, Argentina, Austria and more
- Jul 25, 2025Suzhou Zelgen Biopharmaceuticals’ first study: phase 2 study in Biliary Tract CarcinomaNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT07099547 · 60 planned · China
- Apr 21, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaBeOne Medicines · NCT07554521 · 30 planned · United States
- Jul 22, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaBeOne Medicines · NCT07733180 · 30 planned · Japan
- Sep 18, 2026Beijing Biostar Pharmaceuticals’ first study: phase 2 study in SarcomaNew to Beijing Biostar PharmaceuticalsBeijing Biostar Pharmaceuticals · NCT07842276 · 49 planned · China
- Nov 1, 2026Phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRemeGen · NCT07935369 · 680 planned · China
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Transitional CellBeOne Medicines · NCT03967977
- Oct 30, 2027Primary completion: phase 3 study in Metastatic Gastric AdenocarcinomaBeOne Medicines · NCT07043400
- Dec 2027Primary completion: phase 2 study in Biliary Tract CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT07099547
- Feb 28, 2028Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaBeOne Medicines · NCT07733180
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The newest 60 of 74 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07935369Advanced Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Not yet recruiting | RemeGen | Apr 30, 2030 | 680 |
| NCT07842276Sarcoma · China | 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals | Sep 20, 2028 | 49 |
| NCT07733180Esophageal Squamous Cell Carcinoma · Japan | 2 | Recruiting | BeOne Medicines | Feb 28, 2028 | 30 |
| NCT07554521Esophageal Squamous Cell Carcinoma · United States | 2 | Recruiting | BeOne Medicines | Dec 31, 2031 | 30 |
| NCT07099547Biliary Tract Carcinoma · China | 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Dec 2027 | 60 |
| NCT07043400Metastatic Gastric Adenocarcinoma · United States, Argentina, Austria and more | 3 | Recruiting | BeOne Medicines | Oct 30, 2027 | 351 |
| NCT06944496Stomach Neoplasms · China | 3 | Not yet recruiting | RemeGen | May 15, 2028 | 616 |
| NCT06825494Advanced Solid Tumor · China | 2 | Recruiting | Sino Biopharmaceutical | Mar 2026 | 194 |
| NCT06471673Breast Neoplasms · United States | 2 | Recruiting | briacell-therapeutics-corporation | Apr 30, 2025 | 18 |
| NCT06353360Glioblastoma · China | 2 | Recruiting | jiangsu-healthy-life-innovation-medical-technology-co-ltd | Jul 15, 2025 | 30 |
| NCT06091943Carcinoma, Non-Small-Cell Lung · China, Georgia, Moldova | 1 | Completed | BeOne Medicines | Jul 31, 2025 | 62 |
| NCT05981703Advanced Solid Tumor · United States, Australia, China and more | 1 | Recruiting | BeOne Medicines | Feb 28, 2029 | 337 |
| NCT05906524Advanced HCC · China | 2 | Not yet recruiting | shanghai-kanda-biotechnology-co-ltd | Apr 30, 2025 | 85 |
| NCT05791097Carcinoma, Non-Small-Cell Lung | 3 | Withdrawn | Novartis | Dec 24, 2027 | 0 |
| NCT05840835Advanced Solid Tumor · Brazil | 2 | Recruiting | immix-biopharma-inc | Jan 24, 2024 | 60 |
| NCT05661955Carcinoma, Transitional Cell · China | 2 | Active, not recruiting | BeOne Medicines | May 27, 2025 | 113 |
| NCT05644626Solid Tumors | 1 | Withdrawn | BeOne Medicines | Mar 2025 | 0 |
| NCT05635708Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 2 | Completed | BeOne Medicines | Dec 19, 2025 | 418 |
| NCT05632939Stomach Neoplasms · China | 2 | Active, not recruiting | Beijing Aosaikang Pharmaceutical | Oct 31, 2025 | 62 |
| NCT05609370Colorectal Neoplasms · United States, Australia, China and more | 2 | Active, not recruiting | BeOne Medicines | May 23, 2025 | 113 |
| NCT05577702Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | BeOne Medicines | Dec 13, 2024 | 121 |
| NCT05564338Carcinoma, Hepatocellular | 3 | Withdrawn | BeOne Medicines | Apr 30, 2027 | 0 |
| NCT05516914Neoplasms · China | 2 | Completed | Nanjing Leads Biolabs | Jan 30, 2026 | 98 |
| NCT05505877Parkinson Disease 4, Autosomal Dominant Lewy Body · China | 2 | UNKNOWN | shanghai-gopherwood-biotech-co-ltd | Oct 31, 2024 | 160 |
| NCT05508100Advanced Solid Tumor · China | 1 | Completed | immune-onc-therapeutics | Apr 30, 2024 | 38 |
| NCT05494762Solid Tumor · United States, Australia | 1 | Terminated | BeOne Medicines | Feb 24, 2025 | 55 |
| NCT05461794Esophageal Squamous Cell Carcinoma · China | 2 | Terminated | BeOne Medicines | Feb 26, 2024 | 96 |
| NCT05441046Malignant Solid Tumors · China | 1 | UNKNOWN | Changchun GeneScience Pharmaceutical | Jun 2024 | 120 |
| NCT05267054Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | BeOne Medicines | Aug 30, 2024 | 53 |
| NCT05152147Stomach Neoplasms · Argentina, Australia, Belgium and more | 3 | Active, not recruiting | Jazz Pharmaceuticals | Jul 15, 2026 | 920 |
| NCT05116085Colorectal Neoplasms · China | 2 | Completed | BeOne Medicines | Sep 26, 2023 | 33 |
| NCT05014828Advanced Solid Tumor · China | 2 | Completed | BeOne Medicines | Oct 20, 2023 | 58 |
| NCT04974047Resectable Esophageal Squamous Cell Carcinoma · China | 2 | Completed | BeOne Medicines | Apr 17, 2023 | 70 |
| NCT04948697Advanced Hepatocellular Carcinoma · China, Taiwan | 2 | Completed | BeOne Medicines | Feb 1, 2024 | 94 |
| NCT04921358Carcinoma, Non-Small-Cell Lung · Australia, China | 3 | Terminated | BeOne Medicines | Dec 20, 2023 | 377 |
| NCT04813107Muscle Invasive Bladder Cancer · United States, China | 2 | UNKNOWN | jiangsu-yahong-meditech-co-ltd-aka-asieris | Nov 1, 2023 | 79 |
| NCT04746924Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Terminated | BeOne Medicines | May 30, 2025 | 669 |
| NCT04716634Advanced Solid Tumors · China, Korea, Republic of | 2 | Completed | BeOne Medicines | Feb 22, 2024 | 84 |
| NCT04693234Uterine Cervical Neoplasms · Bulgaria, China, Korea, Republic of and more | 2 | Completed | BeOne Medicines | Jun 16, 2022 | 178 |
| NCT04649385Advanced Solid Tumor · United States, Australia, China and more | 1 | Completed | BeOne Medicines | Oct 17, 2025 | 157 |
| NCT04866017Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more | 3 | Terminated | BeOne Medicines | Oct 17, 2023 | 63 |
| NCT04577963Triple Negative Breast Neoplasms · United States | 2 | Terminated | HUTCHMED | Jun 18, 2024 | 52 |
| NCT04486391Classical Hodgkin Lymphoma · China | 3 | Terminated | BeOne Medicines | Oct 13, 2025 | 3 |
| NCT04425070Lymphoma, T-Cell, Peripheral · China | 2 | Terminated | Antengene | Dec 30, 2025 | 56 |
| NCT04401800Carcinoma, Hepatocellular · China | 2 | Completed | BeOne Medicines | Dec 1, 2022 | 64 |
| NCT04379635Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | BeOne Medicines | Aug 21, 2023 | 453 |
| NCT04363801Stomach Neoplasms · United States, Germany, South Korea | 2 | Terminated | Leap Therapeutics | Mar 31, 2025 | 247 |
| NCT04318080Classical Hodgkin Lymphoma · United States, Australia | 2 | Completed | BeOne Medicines | Dec 12, 2022 | 46 |
| NCT04276493Breast Neoplasms · China, South Korea, Taiwan | 2 | Completed | BeOne Medicines | Dec 7, 2023 | 71 |
| NCT04164199Advanced Malignancies · United States, Australia, China and more | 3 | Completed | BeOne Medicines | May 23, 2026 | 404 |
| NCT04068519Advanced Solid Tumors · China | 2 | Completed | BeOne Medicines | Dec 1, 2018 | 300 |
| NCT04005716Small Cell Lung Carcinoma · China | 3 | Completed | BeOne Medicines | Apr 19, 2023 | 457 |
| NCT04004221Locally Advanced or Metastatic Urothelial Bladder Cancer · China, Korea, Republic of | 2 | Completed | BeOne Medicines | Sep 16, 2019 | 113 |
| NCT03967977Carcinoma, Transitional Cell · China, Taiwan | 3 | Active, not recruiting | BeOne Medicines | Jun 30, 2027 | 420 |
| NCT03957590Esophageal Squamous Cell Carcinoma · China | 3 | Completed | BeOne Medicines | Jan 8, 2025 | 370 |
| NCT03924986Recurrence · China, Taiwan, Thailand | 3 | Completed | BeOne Medicines | Mar 26, 2021 | 263 |
| NCT03783442Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more | 3 | Completed | BeOne Medicines | Feb 28, 2022 | 649 |
| NCT03777657Gastric, or Gastroesophageal Junction Adenocarcinoma · United States, China, France and more | 3 | Completed | BeOne Medicines | Feb 28, 2023 | 997 |
| NCT03745222Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 3 | Terminated | Bristol-Myers Squibb | Jun 26, 2019 | 1 |
| NCT03744468Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in · United States, Australia, France and more | 2 | Completed | BeOne Medicines | Feb 6, 2025 | 147 |
How it is read
Names in the registry
- “Tislelizumab”, 57 entries
- “BGB-A317”, 2 entries
- “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”, 1 entry
- “Tislelizumab (BGB-A317)”, 1 entry
- “Subcutaneous Tislelizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 13 studies
- Esophageal Squamous Cell Carcinoma, 7 studies
- Carcinoma, Hepatocellular, 5 studies
- Stomach Neoplasms, 4 studies
- Hodgkin Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.